AOD-9604 Side Effects: Fat-Loss Peptide Safety Risks
AOD-9604 is marketed for fat loss and metabolic claims, but it is not FDA-approved for these consumer-marketed uses. The FDA states compounded drugs containing AOD-9604 may pose significant immunogenicity risks for certain routes, may involve peptide impurity complexities, and have limited safety-related information; the FDA has also identified serious adverse events that may be associated with AOD-9604, although causality is unclear.
AOD-9604 is marketed for fat loss and metabolic claims, but it is not FDA-approved for these consumer-marketed uses. The FDA states compounded drugs containing AOD-9604 may pose significant immunogenicity risks for certain routes, may involve peptide impurity complexities, and have limited safety-related information; the FDA has also identified serious adverse…
Key Takeaways
- AOD-9604 is not FDA-approved for consumer-marketed weight-loss or metabolic use.
- Its side effects are not well enough characterised for confident safety claims.
- The FDA has noted immunogenicity and impurity concerns, limited safety data, and serious adverse-event reports of unclear causality.
- It is conceptually related to a growth-hormone fragment, but that does not establish efficacy or safety.
- Evidence-based weight management should be clinician-guided and use approved interventions when medication is appropriate.
AOD-9604 at a Glance
| Property | Detail |
|---|---|
| Type | Modified fragment related to human growth hormone |
| FDA approval status | Not approved for consumer-marketed weight-loss or metabolic use |
| Promoted uses | Fat loss, metabolic enhancement, not validated to approved-drug standards |
| Evidence base | Not comparable to approved anti-obesity medicines; scarce rigorous human safety data |
| Compounding status | Nominated then withdrawn; potential significant safety risks |
| Key FDA concern | Immunogenicity, impurities, limited safety data, serious adverse-event reports |
AOD-9604 Side Effects: What Is Known
Marketed weight-loss evidence for AOD-9604 is not comparable to approved anti-obesity medicines, and its safety profile is poorly characterised. The domains below reflect injection-related and immune risks plus FDA-flagged concerns.
| Side Effect Domain | What May Occur | Why It Matters |
|---|---|---|
| Allergic / immune reactions | Rash, swelling, anaphylaxis | FDA notes immunogenicity risk for certain routes |
| Injection-site infection | Redness, warmth, swelling, pus, fever | Non-sterile or contaminated product can cause serious infection |
| Glucose changes | Altered blood sugar | GH-fragment activity may affect metabolism |
| GI symptoms | Nausea, stomach discomfort | Reported among unapproved metabolic peptides |
| Serious adverse events | Unclear, FDA-flagged | Reports exist but causality is uncertain |
| Long-term effects | Unknown | No adequate long-term human data |
Considering AOD-9604 alongside other medicines?
Check it against your full medication list instantly. Allmeds scans the widest drug interaction database in minutes.
Safety Profile in Detail
| Dimension | Research summary |
|---|---|
| Mechanism | AOD-9604 is often described as a modified fragment related to human growth hormone. Promoted metabolic mechanisms are not equivalent to approved anti-obesity drug evidence. |
| Clinical evidence | Evidence for marketed weight-loss use is not comparable to approved anti-obesity medicines. Review literature classifies it among unapproved peptides with scarce rigorous human safety data. |
| Severity | Unknown, with FDA-identified potential significant safety risks and serious adverse-event reports of unclear causality. |
| Symptoms to watch | Allergic reactions, injection-site infection, swelling, rash, unexplained systemic symptoms, glucose changes, or severe GI symptoms. |
| Official guidance | FDA lists AOD-9604 among substances nominated but withdrawn, describing potential immunogenicity and impurity concerns plus limited safety information. |
| Practical patient advice | Avoid gray-market AOD-9604. People seeking weight management should consider approved, clinician-supervised options instead. |
Common Questions About AOD-9604 Side Effects
No, it is not FDA-approved for consumer-marketed weight-loss use.
Not well enough for confident safety claims.
The FDA has noted potential immunogenicity, impurity/API concerns, limited safety data, and serious adverse-event reports of unclear causality.
It is related conceptually to a GH fragment, but that does not establish efficacy or safety.
Evidence-based weight management should be clinician-guided and use approved interventions when medication is appropriate.
Check AOD-9604 against your full medication list
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile, in minutes.
References
- U.S. Food & Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. fda.gov.
- Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). tga.gov.au.
- European Medicines Agency. Product information and EPARs. ema.europa.eu.